JPRN-UMIN000010980招募中2 期
Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancer - HORE CC01
HORE0 个研究点目标入组 120 人开始时间: 2013年6月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •A patient: 1)with administration contraindications for UFT,LV. 2)with active synchronous or metachronous malignancy other than carcinoma in situ(within 5 years). 3)has severe postoperative complications such as serious postoperative infectious disease,anastomotic leak and gastrointestinal bleeding. 4) has severe diarrhea. 5)has severe drug hypersensitivity. 6)is a pregnant woman or a woman suspected of being pregnant,or,is a man who hopes to make his partner pregnant. 7)with psychosis or psychoneurosis. 8)In case that the doctor judged that he/she is disqualified for the enrollment in this clinical trial.
研究者
相似试验
招募中
2 期
A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancerBreast cancerJPRN-UMIN000004586Ryukyu Breast Club140
已完成
不适用
A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.high risk stage II/ stage III colorectal cancerJPRN-UMIN000007696Chiba surgical oncology development association200
进行中（未招募）
1 期
A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)euroendocrine CarcinomasMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000767-17-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS112
进行中（未招募）
1 期
Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancerEUCTR2012-005422-30-DEAIO Studien gGmbH400
已完成
不适用
Phase I randomized study of 0.15% UF-021 in patients with geographic atrophy treated after wet age-related macular degeneratioAge-related macular degeneraitonJPRN-UMIN000007881Dept. of Ophthalmology, Kagawa university faculty of medicine50